椎管内注药辅助治疗结核性脑膜炎的临床观察

The Clinical Observation of Injection Medicine Through Spinal Canal to Treat Tubercular Meningitis Auxiliary

目的探讨在常规抗结核治疗的基础上加用椎管内注药治疗结核性脑膜炎的临床疗效及安全性。方法选取符合标准的患者60例,随机分为观察组和对照组各30例,两组患者均给予常规治疗,观察组加用椎管内注药,比较二者临床疗效。结果入组时两组患者脑脊液白细胞计数和蛋白定量比较,差异无统计学意义(P>0.05);治疗两个月后,两组患者各项指标较入组时均有不同程度改善(P<0.05),但是观察组患者改善更显著(P<0.05)。观察组患者总有效率100%,高于对照组的90%,差异存在显著性(P<0.05)。两组患者在治疗过程中均未出现严重药物不良反应。结论椎管内注药辅助治疗结核性脑膜炎,可短时间内使脑脊液恢复正常和缓解临床症状,是一种安全、有效的治疗方法。

Objective To discuss the clinical effectiveness and safety of added injection drug treatment through spinal canal on the basis of routine anti-tuberculosis treatment for tuberculous meningitis. Methods Selected sixty cases standard patients, randomly divided them into observation group and control group each with 30 cases, all patients of the two groups were given conventional treatment, patients in observation group were added injection drug through spinal canal, compare the clinical effect. Results Compare the white blood cell count and protein quantitative of cerebrospinal fluid of the two groups when beginning, the difference wasn＇t display statistically significant （P 〉 0.05）; After 2 months of treatment, the indicators of the two groups＇ patients are differently improved （P 〈 0.05）, but the observation group improved more significant （P 〈 0.05）. The total effective rate of observation group is 100%, higher than that of the control group which is 90%, the difference is significant （P 〈 0.05）. No patient appear serious adverse drug reactions in treatment. Conclusion Injection medicine through spinal canal to treat tubercular meningitis auxiliary is a safe and effective treatment, can recover cerebrospinal fluid to normal and relieve the clinical symptoms in a short time.